2014 Volume 25 Issue 2 Pages 57-61
The establishment of the treatment for warfarin-induced hemorrhagic infarction is essential because there is no effective treatment for hemorrhagic infarction at present and an exacerbation of hemorrhagic infarction with warfarin is mortal. Cilostazol, an antiplatelet agent, have various protective effects, including neuroprotective effect and protective effects on vascular endothelial cells, however it is careful administration for warfarin treatment patients. In the present study, we found that cilostazol suppressed the exacerbation of warfarin-induced hemorrhagic infarction by the enhancement of tight junction proteins and VE-cadherin. Furthermore, we suggested that this combination treatment is available clinically because this combination treatment was not extend bleeding time from the murine tail vein.